BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35790278)

  • 1. Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
    Sato J; Nakano K; Shimizu T; Uchida M
    Anticancer Res; 2022 Jul; 42(7):3575-3582. PubMed ID: 35790278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
    Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
    LeClair JN; Merl MY; Cohenuram M; Luon D
    Clin Lung Cancer; 2022 Jan; 23(1):34-42. PubMed ID: 34556401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
    Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
    Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
    Naidoo J; Vansteenkiste JF; Faivre-Finn C; Özgüroğlu M; Murakami S; Hui R; Quantin X; Broadhurst H; Newton M; Thiyagarajah P; Antonia SJ
    Lung Cancer; 2022 Apr; 166():84-93. PubMed ID: 35245844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab.
    Shaverdian N; Thor M; Shepherd AF; Offin MD; Jackson A; Wu AJ; Gelblum DY; Yorke ED; Simone CB; Chaft JE; Hellmann MD; Gomez DR; Rimner A; Deasy JO
    Cancer Med; 2020 Jul; 9(13):4622-4631. PubMed ID: 32372571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
    Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
    Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database.
    Sato J; Uchida M; Wakabayashi H; Shimizu T
    Anticancer Res; 2022 Jun; 42(6):3109-3116. PubMed ID: 35641286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
    Wang Y; Zhang T; Huang Y; Li W; Zhao J; Yang Y; Li C; Wang L; Bi N
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1154-1164. PubMed ID: 34963558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
    Kanbayashi Y; Shimizu T; Kojima A; Anzai M; Kawai R; Uchida M
    Sci Rep; 2023 May; 13(1):8819. PubMed ID: 37258564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer.
    Shibata Y; Murakami S
    Expert Opin Drug Saf; 2020 Jun; 19(6):653-659. PubMed ID: 32357806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Saito G; Oya Y; Taniguchi Y; Kawachi H; Daichi F; Matsumoto H; Iwasawa S; Suzuki H; Niitsu T; Miyauchi E; Yokoi T; Yokoyama T; Uenami T; Sakata Y; Arai D; Okada A; Nagata K; Teraoka S; Kokubo M
    Lung Cancer; 2021 Nov; 161():86-93. PubMed ID: 34543942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    Borghaei H; Redman MW; Kelly K; Waqar SN; Robert F; Kiefer GJ; Stella PJ; Minichiello K; Gandara DR; Herbst RS; Papadimitrakopoulou VA
    Clin Lung Cancer; 2021 May; 22(3):178-186. PubMed ID: 33358401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Lung Toxicity With Lenalidomide Using the Pharmacovigilance Database.
    Sato J; Eren T; Murata S; Shimizu T; Uchida M
    Anticancer Res; 2022 Dec; 42(12):5917-5925. PubMed ID: 36456140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
    Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
    Bruni A; Scotti V; Borghetti P; Vagge S; Cozzi S; D'Angelo E; Giaj Levra N; Fozza A; Taraborrelli M; Piperno G; Vanoni V; Sepulcri M; Trovò M; Nardone V; Lattanzi E; Bou Selman S; Bertolini F; Franceschini D; Agustoni F; Jereczek-Fossa BA; Magrini SM; Livi L; Lohr F; Filippi AR
    Front Oncol; 2021; 11():744956. PubMed ID: 34650927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.